Medical device registration in the GCC should be planned around the requirements of each target market. Official pathways include EDE’s medical-device marketing authorisation service in the UAE, SFDA’s marketing authorisation requirements in Saudi Arabia and NHRA’s registration process in Bahrain. (Source: NHRA)
Discover the HERMS life sciences platform and our regulatory affairs expertise.
Rather than assuming that approval in one country permits sales throughout the region, build a country-specific regulatory plan. The plan should connect product classification, documentation readiness, local representation and commercial partner selection.
Start with the product and intended use
Before preparing applications, establish a clear description of the device, its intended purpose, intended users and supplied configurations. Include accessories, software components and model variations in the internal product assessment.
For UAE products requiring classification clarification, EDE’s classification service determines the regulatory category and whether marketing authorisation is required. Saudi Arabia’s medical-device marketing authorisation requirements also include risk-classification rules. (Source: EDE)
Use the outcome of this assessment to define the proposed submission scope in each market. Avoid grouping products solely because they share a brand name or commercial catalogue.
Understand the registration pathway in each GCC market
The following overview identifies official starting points rather than providing an exhaustive registration checklist. Confirm the current requirements and any applicable transition arrangements before committing to a launch schedule.
- United Arab Emirates: EDE provides the medical-device marketing authorisation service and states that Marketing Authorisation Holders and manufacturing sites must be registered before product registration; the relevant marketing office or medical warehouse must also hold a valid EDE licence. (Source: EDE)
- Saudi Arabia: SFDA sets the requirements for Medical Devices Marketing Authorization (MDMA), while its implementing regulation requires manufacturers located outside the Kingdom to appoint an authorised representative. (Source: SFDA)
- Bahrain: NHRA’s current registration page directs applications through the Madar system, submitted by an establishment registered with NHRA as a Medical Device Authorized Representative. (Source: NHRA)
- Oman: The Ministry of Health’s registration service lists local medical-device establishment approval, manufacturer registration and agency documentation among its prerequisites. (Source: Ministry of Health)
- Kuwait: The Ministry of Health publishes Ministerial Decree No. 13 of 2022 concerning the registration and release of medical devices in its official decrees and circulars directory. Confirm the product-specific registration and release requirements before shipment. (Source: Ministry of Health)
- Qatar: The Ministry of Public Health’s implantable-device guideline requires local facilities to obtain registration approval before importing implantable medical devices. This guidance is specific to implantable devices and should not be presented as a universal pathway for every device category. (Source: MoPH Qatar)
Build a reusable documentation package
Prepare a controlled core documentation package, then assess the additional requirements for each country. Treat the following as an organisational framework rather than a universal GCC submission checklist.
- Manufacturer records: Maintain current legal-entity details, manufacturing-site information and relevant licences.
- Product information: Organise intended-use statements, model lists, accessories, specifications and device descriptions.
- Quality and conformity evidence: Review applicable quality-system certificates, declarations of conformity and supporting regulatory certificates.
- Technical evidence: Identify the safety, performance and other supporting documentation relevant to the device.
- Labelling materials: Maintain controlled packaging artwork, instructions for use and translations.
- Local arrangements: Prepare the relevant authorisation letters, representation agreements and applicant documentation.
- Lifecycle planning: Assign responsibility for renewals, product changes, complaints and post-market activities.
For example, EDE requests free-sale or registration certificates, conformity evidence, product information and agency documentation, while Qatar’s implantable-device guideline includes manufacturer authorisation and a post-marketing surveillance plan. Use these differences to build a country-by-country gap assessment instead of submitting the same package unchanged. (Source: MoPH Qatar)
Align distributor selection with regulatory responsibilities
Evaluate prospective distributors and local partners against both commercial objectives and the responsibilities they are expected to perform. Consider product experience, customer coverage, technical support, documentation handling and the resources available for ongoing regulatory coordination.
Do not use “distributor,” “importer” and “authorised representative” interchangeably in agreements. In Saudi Arabia, for example, the authorised representative has defined licensing and regulatory responsibilities under SFDA’s implementing regulation. (Source: SFDA)
Before appointing a partner, document who will manage submissions, hold relevant records, coordinate authority communications and support product changes. Include arrangements for access to documentation and continuity if the commercial relationship ends.
Plan beyond the initial submission
Build the market-entry schedule around dependencies, including local establishment readiness, manufacturer documentation, translations and responses to authority questions. Avoid treating a planned submission date as a guaranteed commercial launch date.
Once approval is obtained, maintain a market-specific record of certificates, approved product configurations and assigned responsibilities. Review planned product or partner changes before implementation so their regulatory implications can be assessed.
For Saudi medical-device reporting guidance, see reporting medical-device adverse events and incidents. For HERMS’s overview, see adverse-event reporting and ICSR processing.
How HERMS supports GCC market entry
HERMS provides consultancy and advisory support across regulatory affairs, market access and commercial development. We support registration dossier preparation and help pharmaceutical and healthcare companies identify suitable distributors and evaluate local partners.
Planning medical device registration in the GCC? Contact HERMS to discuss your target markets, documentation readiness and partner-selection needs. Contact HERMS